XOMA(US:XOMA)2026-03-18 20:05Financial Performance - In 2025, XOMA received total cash receipts of $50.5 million, comprising $33.6 million from commercial payments and $16.9 million from milestone payments and other fees[35]. - The company generated a net income of $31.7 million and cash flows from operations of $2.9 million for the year ended December 31, 2025, but has an accumulated deficit of $1.2 billion[152]. - Company received commercial payments of $1.7 million in 2025 and $1.6 million in 2024 under the Aptevo CPPA[57]. - The company has authorized a stock repurchase program allowing for the purchase of up to $50.0 million of its common stock through January 2027[98]. - As of December 31, 2025, the company had repurchased 648,708 shares for a total of $16.1 million[99]. Portfolio and Assets - The company has a diversified portfolio with economic rights to over 120 assets, including seven commercial-stage assets and 14 late-stage therapeutic candidates[38]. - XOMA's portfolio includes assets with significant commercial sales potential, primarily in Phase 1 and 2 development stages[36]. - The company has added 22 milestone and royalty interests to its portfolio since the beginning of 2025[38]. - Company acquired rights to receive potential regulatory and commercial milestone payments of up to $342.7 million and royalties on net sales of aldoxorubicin in the low to mid-teens percentage range for orphan indications[52]. - Company acquired Pulmokine for $20.0 million, with eligibility for low to mid-single-digit royalties on commercial sales of seralutinib[70]. Revenue Streams - The commercial asset VABYSMO® generated $22.5 million in royalties for XOMA in 2025, with a royalty rate of 0.5% on future net sales[40]. - XOMA earned $7.7 million in royalties from OJEMDA in 2025, following its FDA approval in April 2024[50]. - The company is eligible for mid-single-digit royalties on sales of OJEMDA, with additional milestone payments received in 2025 totaling $15 million[49]. - Company paid $22.0 million for 100% of remaining royalties related to XACIATO, with royalties ranging from low to high single digits[58]. - The company is eligible to receive milestone payments of up to $20.8 million related to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products under the Takeda Collaboration Agreement[83]. Acquisitions and Transactions - XOMA's strategy includes acquiring additional milestone and royalty revenue streams, having closed seven transactions since the beginning of 2025, adding approximately $11.7 million in cash and cash equivalents[37]. - Company entered into the Twist RPA for $15.0 million, eligible to receive up to $0.5 billion in milestone payments and low single-digit royalties[75]. - Company acquired an economic interest in DSUVIA for $8.0 million, with potential royalties of 15% on commercial sales[60]. - The company plans to continue business development efforts to acquire potential milestone and royalty streams or companies, with future growth dependent on the availability of suitable products at acceptable prices and terms[175]. - The company may seek to expand market opportunities by acquiring securities from other biopharmaceutical companies, which could involve risks and uncertainties[124]. Risks and Challenges - The company faces competition from other firms seeking to aggregate royalties and provide financing to biotechnology companies, which may impact its market position[103]. - A significant portion of the company's portfolio value is concentrated in a limited number of products, indicating that the failure of any one product could materially impact financial results[112]. - The company may face challenges in integrating acquired assets, which could disrupt operations and dilute shareholder value[121]. - The company is dependent on third parties to achieve development milestones and product sales, which could affect financial performance[112]. - The company may not be able to realize anticipated benefits from acquisitions or in-licensing due to integration risks and unforeseen challenges[176]. Regulatory and Market Conditions - Regulatory approvals for development-stage product candidates are subject to extensive requirements, and unknown problems may lead to marketing restrictions or product withdrawals[129]. - The company’s potential royalty providers may face significant delays in clinical trials due to various factors, including patient enrollment challenges and regulatory requirements[187]. - Changes in regulatory policies under the current U.S. Presidential administration may create uncertainty for the company's licensees and their business operations[148]. - The introduction of generic drugs can significantly reduce sales of branded products, adversely affecting potential milestones and royalties[210]. - The FDA's interpretation of orphan drug exclusivity may change, affecting the competitive landscape for drugs with orphan designation[198]. Intellectual Property - The company and its potential royalty providers rely on patent protection, copyright, trade secret, and trademark laws to safeguard proprietary technology, but these protections may be limited[226]. - The validity and enforceability of issued patents are uncertain, and U.S. patents may be subject to post-grant review procedures that could result in the loss of valuable patent rights[229]. - Inadequate protection of intellectual property rights could hinder the commercialization of technologies or products, negatively impacting sales and market share[230]. - The biotechnology patent landscape is highly uncertain, with evolving legal standards that may affect the validity of patents[230]. - Competitors may design around existing patents or develop superior technologies, impacting the company's market position[233].